Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008.

"Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and we look forward to the results of the Canadian/European trial (MAESTRO-01) in the second half of this year," said Kevin Giese, President and CEO of BioMS Medical. "Our hope is that the results of this trial will confirm that dirucotide is able to significantly slow the progression of MS, specifically in patients with secondary progressive multiple sclerosis."

Currently, BioMS is conducting two clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

        -  MAESTRO-01: On January 22, 2007, BioMS announced that this pivotal
           phase III trial, being conducted in Canada and Western Europe, had
           completed full recruitment of 611 SPMS patients at 47 trial sites
           in ten countries. To date, there have been nine positive safety
           reviews from the Data Safety Monitoring Board (DSMB). The primary
           clinical endpoint for MAESTRO-01 (and MAESTRO-03) is defined as a
           statistically and clinically significant increase in the time to
           progression of the disease as measured by the Expanded Disability
           Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4
           immune response genes.

           On August 13, 2008, the DSMB conducted a scheduled interim
           analysis of efficacy and safety and recommended that the trial
           continue to completion. The interim analysis evaluated the first
           200 patients to complete MAESTRO-01 and assessed the likelihood of
           the study reaching
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014  ARCH Venture Partners, one of ... the development of seed and early-stage advanced technology ... closed with more than $400 million in subscriptions. ... subscription target by more than $150 million. ... strength and potential of our approach to finding ...
(Date:8/27/2014)... After the boom of the energy ... beverage craze is going to be the stress relief ... use Stress Relief energy pattern which can be applied ... a beverage, including minerals, herbs and liquids. Stress Relief ... power into rapid recovery and helping to adapt more ...
(Date:8/27/2014)... 2014 Budding Biomedical Scientists , ... School participated in the Scientific Enrichment and ... School of Medicine . , The ... professional experience in the sciences and brings them ... and students for both academic and career mentoring. ...
(Date:8/26/2014)... 2014 An analysis by Replikins, Ltd. of ... Mers CoV virus strains has revealed extensive conservation ... This conservation and sharing of specific Replikin gene structures ... candidate, as it did for the H5N1 influenza vaccine ... have been found to be effective (1,2). ...
Breaking Biology Technology:Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2
... Gov. Jim Doyle has announced that Berbee ... Fitchburg Technology Campus, will receive $250,000 in state Technology Zone ... in a new 43,250-square-foot office building and a 51,500-square-foot data ... the Fitchburg Technology Campus. , ,The project is expected ...
... Madison company that is developing drugs to protect cancer ... has closed on a Series A Preferred Stock financing ... , ProCertus BioPharm , an oncology-based pharmaceutical company, will ... patients to demonstrate proof-of-concept in humans for its chemo- ...
... a patient presents to a doctor, many assessments have to ... of what is unglamorously called managing the patient. , ,During ... would have us believe, one of the most important judgment ... or not. This is not in the sense that ...
Cached Biology Technology:ProCertus BioPharm secures $2.3M in financing 2ProCertus BioPharm secures $2.3M in financing 3Barriers will not stop convergence of medical technologies 2Barriers will not stop convergence of medical technologies 3Barriers will not stop convergence of medical technologies 4Barriers will not stop convergence of medical technologies 5Barriers will not stop convergence of medical technologies 6Barriers will not stop convergence of medical technologies 7
(Date:8/27/2014)... are often depicted as giant, frightening beasts. But every ... of a rock slab containing fossils of 24 very ... a group of hatchlings overseen by a caretaker, according ... , Penn,s Brandon P. Hedrick and Peter Dodson led ... of Natural History, where the specimen is held. Hedrick ...
(Date:8/27/2014)... are willing to pay a premium for fruits, vegetables ... what the label claims is another matter. Now scientists ... way to make sure farms are labelling their produce ... of Agricultural and Food Chemistry , could help prevent ... and Food Safety Authority and the Wuerzburg University note ...
(Date:8/27/2014)... lost or abandoned each year in U.S. waters and ... to catch fish, crabs, and other species such as ... and the watermen who depend on the resources--losses that ... study. , The report, published in the Marine ... to examine the derelict fish trap problem, and so-called ...
Breaking Biology News(10 mins):Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2
... of questions, but sometimes traditional techniques are superior. Authorities ... when they relied upon statistical data to monitor moose ... indigenous group of people living in the James Bay ... have lived in harmony with their environment. They hunt ...
... southern limit of permanently frozen ground, or permafrost, is now ... in the James Bay region, according to two researchers from ... issue of the scientific journal Permafrost and Periglacial Processes ... trend continues, permafrost in the region will completely disappear in ...
... This release is available in Spanish . ... reliably mark termites and other insects over vast acreage so ... the previous methodand more affordable. That,s according to ... agency,s U.S. Arid-Land Agricultural Research Center in Maricopa, Ariz., and ...
Cached Biology News:Listen to the natives for better moose monitoring 2Permafrost line recedes 130 km in 50 years 2New assay helps track termites and other insects 2
Incomplete Adjuvant...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
PGF1α-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGF1α by GC- or LC-mass spectrometry....
PGD2-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGD2 by GC- or LC-mass spectrometry....
Biology Products: